Nutraceutical approaches in the management of cardiovascular dysfunctions associated with diabetes mellitus

Diabetic Cardiomyopathy: Biochemical and Molecular Mechanisms

Volumn , Issue , 2014, Pages 377-396

  Daftardar, Saloni ^a   Kaur, Ginpreet ^a   Addepalli, Veeranjaneyulu ^a  

^a Shri Vile Parle Kelavani Mandal's Narsee Monjee Institute of Management Studies   (India)

Author keywords

Antidiabetic; Herbs; Inflammation; Insulin resistance; Nutraceuticals

Indexed keywords

EID: 84936854657     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-9317-4_24     Document Type: Chapter

References (67)

1. World Health Organization (2008) Traditional medicine. http://www.who.int/mediacentre/ factsheets/fs134/en/
2. Zarraga I, Schwartz E (2006) Impact of dietary patterns and interventions on cardiovascular health. Circulation 114:961-973
3. Retelny VS, Neuendorf A, Roth JL (2008) Nutrition protocols for the prevention of cardiovascular disease. Nutr Clin Pract 23:468-476
4. Dureja H, Kaushik D, Kumar V (2003) Developments in nutraceuticals. Indian J Pharmacol 35:363-372
5. Jaap GN, Jerrold MO (2006) Infl amed fat: what starts the fi re. J Clin Invest 116:33-35
6. Grundy SM, Brewer HB, Cleeman JI et al (2004) Defi nition of metabolic syndrome: report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientifi c issues related to defi nition. Circulation 109:433-438
7. Jaswinder KS, Gokhan SH (1999) The role of TNF in adipocyte metabolism. Semin Cell Dev Biol 10:19-29
8. Stefan N, Vozarova B, Funahashi T et al (2002) Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51:1884-1888
9. He Z, Rask-Madsen C, King GL (2003) Managing heart disease: mechanisms of cardiovascular complications in diabetes and potential new pharmacological therapies. Eur Heart J Suppl 5(Suppl B):B51-B57
10. Perseghin G, Scifo P, Cobelli FD et al (1999) Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1 H-13 C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48:1600-1606
11. Tripathy D, Dandona P (2002) Acute elevation of plasma free fatty acids increases reactive oxygen species (ROS) generation by polymorphonuclear cells, induces nuclear factor-kB (NFkB) and impairs brachial artery reactivity in healthy subjects. In: 62nd Scientifi c Sessions of the American Diabetes Association, San Francisco
12. Wellen KE, Hotamisligil GS (2005) Infl ammation, stress and diabetes. J Clin Invest 115:1111-1119
13. Hotamisligil GS, Peraldi P, Budavari A et al (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 271:665-668
14. Dong M, Su D, Coudriet GM, Hyun Kim D et al (2009) FoxO1 links insulin resistance to proinfl ammatory cytokine IL-1ß production in macrophages. Diabetes 58(11):2624-2633
15. Dzau V, Braunwald E (1999) Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 121:1244-1263
16. Ross R (1999) Atherosclerosis-an infl ammatory disease. N Engl J Med 340:115-126
17. Woollard KJ, Geissmann F (2010) Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 7:77-86
18. Vallance P, Chan N (2001) Endothelial function and nitric oxide: clinical relevance. Heart 85:342-350
19. Landmesser U, Hornig B, Drexler H (2004) Endothelial function: a critical determinant in atherosclerosis. Circulation 109:11-27
20. Deanfield JE, Halcox JP, Rabelink TJ (2007) Endothelial function and dysfunction: testing and clinical relevance. Circulation 115:1285-1295
21. Hamilton CA, Miller WH, Brosnan MJ et al (2004) Strategies to reduce oxidative stress in cardiovascular disease. Clin Sci (Lond) 106:219-234
22. Taniyama Y, Griendling KK (2003) Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42:1075-1081
23. Droge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 82:47-95
24. Griendling KK, FitzGerald GA (2003) Oxidative stress and cardiovascular injury. Part II: Animal and human studies. Circulation 108:2034-2040
25. Jay D, Hitomi H, Griendling KK (2006) Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med 40:183-192
26. Packard CJ, Caslake M, Shepherd J (2000) The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol 74:S17-S22
27. Ginsberg H, Zhang YL, Antonio H (2005) Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 36:232-240
28. Reaven GM, Chen YD, Jeppesen J et al (1993) Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 92:141-146
29. Shaul PW (2003) Regulation of endothelial nitric oxide synthase. Annu Rev Physiol 64(749):774
30. Pariza MW, Park Y, Cook ME (2000) Mechanisms of action of conjugated linoleic acid: evidence and speculation. Proc Soc Exp Biol Med 223:8-13
31. Lee K, Kritchevsky D, Pariza M (1994) Conjugated linoleic acid and atherosclerosis in rabbits. Atherosclerosis 8:19-25
32. Ryder JW, Portocarrero CP, Song XM et al (2001) Isomer-specifi c antidiabetic properties of conjugated linoleic acid. Diabetes 50:1149-1157
33. Evans M, Brown J, McIntosh M (2002) Isomer-specifi c effects of conjugated linoleic acid (CLA) on adiposity and lipid metabolism. J Nutr Biochem 13:508-516
34. Grundy SM, Denke MA (1990) Dietary infl uences on serum lipids and lipoproteins. J Lipid Res 31:1149-1172
35. De Lorgeril M, Salen P, Martin JL et al (1999) Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: fi nal report of the Lyon diet heart study. Circulation 99:779-785
36. Kris-Etherton PM, Taylor DS, Yu-Poth S et al (2000) Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr 71(Suppl 1):179S-188S
37. Mori TA, Bao DQ, Burke V et al (1999) Docosahexanoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 34:253-260
38. Hartweg J, Farmer AJ, Perera R et al (2007) Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 50:1593-1602
39. Lau FC, Bagchi M, Sen CK et al (2008) Nutrigenomic basis of benefi cial effects of chromium (III) on obesity and diabetes. Mol Cell Biochem 317:1-10
40. Anderson RA, Cheng N, Bryden NA et al (1997) Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 46(11):1786-1791
41. Broadhurst CL, Domenico P (2006) Clinical studies on chromium picolinate supplementation in diabetes mellitus: a review. Diabetes Technol Ther 8(6):677-687
42. Balon TW, Gu JL, Tokuyama Y et al (1995) Magnesium supplementation reduces development of diabetes in rat model of spontaneous non-insulin dependent diabetes mellitus. Am J Physiol 269:E745-E752
43. Kendall MJ, Nuttall SL, Martin U (1998) Antioxidant therapy-a new therapeutic option for reducing mortality from coronary artery disease. J Clin Pharm Ther 23:323-325
44. Riccioni G, Bucciarelli T, Mancini B et al (2007) Antioxidant vitamin supplementation in cardiovascular diseases. Ann Clin Lab Sci 37:89-95
45. Devaraj S, Jialal I (2000) Low-density lipoprotein postsecretory modifi cation, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation. Circulation 102:191-196
46. Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular morbidity and mortality associated with metabolic syndrome. Diabetes Care 24:683-689
47. Gaede P, Poulsen HE, Parving HH et al (2001) Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients. Diabet Med 18:756-760
48. Singh U, Jiala I (2008) Alpha-lipoic acid supplementation and diabetes. Nutr Rev 66: 646-657
49. Kanter M, Meral I, Yener Z et al (2003) Partial regeneration/proliferation of the ß-cells in the islets of Langerhans by Nigella sativa L. in streptozotocin-induced diabetic rats. Tohoku J Exp Med 201:213-219
50. Fararh KM, Atoji Y, Shimizu Y et al (2002) Insulinotropic properties of Nigella sativa oil in streptozotocin plus nicotinamide diabetic hamster. Res Vet Sci 73:279-282
51. Meral I, Yener Z, Kahraman T et al (2001) Effect of Nigella sativa on glucose concentration, lipid peroxidation, antioxidant defense system and liver damage in experimentally-induced diabetic rabbits. J Vet Med A Physiol Pathol Clin Med 48:593-599
52. El-Dakhakhny M, Mady N, Lembert N et al (2002) The hypoglycaemic effect of Nigella sativa oil is mediated by extrapancreatic actions. Planta Med 68:463-464
53. Morikawa T, Xu F, Ninomiya K et al (2004) Nigellamines A3, A4, A5 and C, new dolabellanetype diterpene alkaloids, with lipid metabolism-promoting activities from the Egyptian medicinal food black cumin. Chem Pharm Bull 52:494-497
54. Sitasawad SL, Shewade Y, Bhonde R (2000) Role of bitter gourd fruit juice in STZ-induced diabetic state in vivo and in vitro. J Ethnopharmacol 73:71-79
55. Karunanayake EH, Jeevathayaparan S, Tennekoon KH (1990) Effect of Momordica charantia fruit juice on streptozotocin-induced diabetes in rats. J Ethnopharmacol 30:199-204
56. Welihinda J, Arvidson G, Gylfe E et al (1982) The insulin-releasing activity of the tropical plant Momordica charantia . Acta Biol Med Ger 41:1229-1240
57. Hannan JM, Ali L, Rokeya B et al (2007) Soluble dietary fi bre fraction of Trigonella foenumgraecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption and enhancing insulin action. Br J Nutr 97:514-521
58. Effect of fenugreek on blood sugar and insulin in diabetic humans. http://clinicaltrials.gov
59. Moorthy R, Prabhu KM, Murthy PS (2010) Anti-hyperglycemic compound (GII) from fenugreek ( Trigonella foenum-graecum Linn.) seeds: purifi cation and effect in diabetes mellitus. Indian J Exp Biol 48:1111-1118
60. Mohamed GA (2013) Alliuocide A: a new antioxidant fl avonoid from Allium cepa L. Phytopharmacology 4:220-227
61. Cheng HY, Lin TC, Yu KH et al (2003) Antioxidant and free radical scavenging activities of Terminalia chebula . Biol Pharm Bull 26:1331-1335
62. Kim JH, Hong C, Koo YC et al (2011) Oral administration of ethyl acetate soluble portion of Terminalia chebula conferring protection from streptozotocin-induced diabetes mellitus and its complications. Biol Pharm Bull 34:1702-1709
63. Sschmidt AM, Yan SD, Wautier JL et al (1999) Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84:489-497
64. Hartge M, Unger T, Kintscher U (2007) The endothelium and vascular infl ammation in diabetes. Diab Vasc Dis Res 4:84-88
65. Navarro J, Mora C (2005) Role of infl ammation in diabetic complications. Nephrol Dial Transplant 20:2601-2604
66. Festa A, Haffner S (2005) Infl ammation and cardiovascular disease in patients with diabetes: lessons from the Diabetes Control and Complications Trial. Circulation 111:2414-2415
67. Omara E, Kama A, Alqahtani A et al (2010) Herbal medicines and nutraceuticals for diabetic vascular complications: mechanisms of action and bioactive phytochemicals. Curr Pharm Des 16:3776-3807